Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,062 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Factors associated with the response to atezolizumab/bevacizumab combination therapy for hepatocellular carcinoma.
Yano Y, Yamamoto A, Mimura T, Kushida S, Hirohata S, Yoon S, Hirano H, Kim SK, Hatazawa Y, Momose K, Hayashi H, Kado T, Nishi K, Tanaka H, Matsuura T, Yoshida R, Asaji N, Yasutomi E, Shiomi Y, Minami A, Komatsu S, Fukumoto T, Ueda Y, Kodama Y. Yano Y, et al. Among authors: kim sk. JGH Open. 2023 Jun 15;7(7):476-481. doi: 10.1002/jgh3.12932. eCollection 2023 Jul. JGH Open. 2023. PMID: 37496817 Free PMC article.
Outcome of double-filtration plasmapheresis plus interferon treatment in nonresponders to pegylated interferon plus ribavirin combination therapy.
Sugimoto K, Kim SR, El-Shamy A, Imoto S, Fujioka H, Kim KI, Tanaka Y, Yano Y, Kim SK, Hasegawa Y, Fujinami A, Ohta M, Hatae T, Hotta H, Hayashi Y, Kudo M. Sugimoto K, et al. Among authors: kim sr, kim sk, kim ki. Dig Dis. 2013;31(5-6):434-9. doi: 10.1159/000355241. Epub 2013 Nov 21. Dig Dis. 2013. PMID: 24281017 Free article. Clinical Trial.
Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma.
Sugimoto K, Kim SR, Kim SK, Imoto S, Tohyama M, Kim KI, Ohtani A, Hatae T, Yano Y, Kudo M, Hayashi Y. Sugimoto K, et al. Among authors: kim sr, kim sk, kim ki. Oncology. 2015;89 Suppl 2:42-6. doi: 10.1159/000440630. Epub 2015 Nov 19. Oncology. 2015. PMID: 26584035
Significance of post-progression therapy after tyrosine kinase inhibitors for advanced hepatocellular carcinoma.
Yano Y, Yamamoto A, Minami A, Momose K, Mimura T, Kim SK, Hayashi H, Kado T, Hirano H, Hirohata S, Yoon S, Nishi K, Tei H, Tanaka H, Oouchi S, Matsuura T, Yasutomi E, Hatazawa Y, Shiomi Y, Ueda Y, Kodama Y; Kobe Liver Conference (KLC). Yano Y, et al. Among authors: kim sk. JGH Open. 2022 May 25;6(6):427-433. doi: 10.1002/jgh3.12772. eCollection 2022 Jun. JGH Open. 2022. PMID: 35774348 Free PMC article.
Eosionophilic pseudotumor of the liver due to Ascaris suum infection.
Kim S, Maekawa Y, Matsuoka T, Imoto S, Ando K, Mita K, Kim H, Nakajima T, Ku K, Koterazawa T, Fukuda K, Yano Y, Nakaji M, Kudo M, Kim K, Hirai M, Hayashi Y. Kim S, et al. Hepatol Res. 2002 Aug;23(4):306. doi: 10.1016/s1386-6346(01)00187-5. Hepatol Res. 2002. PMID: 12191679
7,062 results